研究单位：[1]Sun Yat-sen University,Sun Yat-sen University[2]The First Affiliated Hospital of Anhui Medical University[3]Liaoning Cancer Hospital & Institute[4]Guangdong Provincial Hospital of Traditional Chinese Medicine[5]Tianjin Medical University Cancer Institute and Hospital[6]Zhejiang Cancer Hospital[7]First Hospital of China Medical University[8]The Affiliated Tumor Hospital of Guangxi Medical University[9]Hangzhou First People's Hospital, School of Medicine, Zhejiang Universiry[10]The Affiliated Hospital of Qingdao University[11]Guangdong Provincial People's Hospital[12]Sichuan Cancer Hospital and Research Institute[13]National Clinical Research Center for Cancer/Cancer Hospital[14]Sun Yat-sen University Cancer Center,Guangzhou 1809858,Guangdong 1809935,China,510060
Patients with histologically confirmed gastric adenocarcinoma with locally advanced gastric cancer are randomized in a 1:1 ratio to receive neoadjuvant chemoradiotherapy with DT45Gy/25f plus three cycles of XELOX therapy or neoadjuvant chemotherapy alone using XELOX regimen following D2 gastrectomy and adjuvant chemotherapy for 3 cycles. The primary end point is 3-year disease free survival (DFS), and secondary end point is 5-year overall survival (OS), R0 resection rate, pathological complete remission (pCR) and treatment safety.
